Showing 63,921 - 63,940 results of 122,660 for search '(( 2 e decrease ) OR ( 5 ((wt decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 2.23s Refine Results
  1. 63921

    N‑Heterocyclic Carbenes with a <i>N</i>‑2,4-Dinitrophenyl Substituent: Comparison with PPh<sub>3</sub> and IPr by Tetsuo Sato (2010571)

    Published 2012
    “…Rh and Au complexesRhCl­(<b>2a</b>)­(cod) [<b>3a</b> (cod = 1,5-cyclooctadiene)], RhCl­(<b>2b</b>)­(cod) (<b>3b</b>), RhCl­(<b>2a</b>)­(CO)<sub>2</sub> (<b>4a</b>), RhCl­(<b>2b</b>)­(CO)<sub>2</sub> (<b>4b</b>), and AuCl­(<b>2a</b>) (<b>5a</b>)were synthesized using <b>2a</b>·HBr and <b>2b</b>·HOTf. …”
  2. 63922

    Table_1_Early transient dysautonomia predicts the risk of infantile epileptic spasm syndrome onset: A prospective cohort study.DOCX by Ipsita Goswami (14292725)

    Published 2022
    “…There was a trend toward decreasing CSI and DFA α1 and increasing CVI in the first 8 months of age.…”
  3. 63923

    N‑Heterocyclic Carbenes with a <i>N</i>‑2,4-Dinitrophenyl Substituent: Comparison with PPh<sub>3</sub> and IPr by Tetsuo Sato (2010571)

    Published 2012
    “…Rh and Au complexesRhCl­(<b>2a</b>)­(cod) [<b>3a</b> (cod = 1,5-cyclooctadiene)], RhCl­(<b>2b</b>)­(cod) (<b>3b</b>), RhCl­(<b>2a</b>)­(CO)<sub>2</sub> (<b>4a</b>), RhCl­(<b>2b</b>)­(CO)<sub>2</sub> (<b>4b</b>), and AuCl­(<b>2a</b>) (<b>5a</b>)were synthesized using <b>2a</b>·HBr and <b>2b</b>·HOTf. …”
  4. 63924

    N‑Heterocyclic Carbenes with a <i>N</i>‑2,4-Dinitrophenyl Substituent: Comparison with PPh<sub>3</sub> and IPr by Tetsuo Sato (2010571)

    Published 2012
    “…Rh and Au complexesRhCl­(<b>2a</b>)­(cod) [<b>3a</b> (cod = 1,5-cyclooctadiene)], RhCl­(<b>2b</b>)­(cod) (<b>3b</b>), RhCl­(<b>2a</b>)­(CO)<sub>2</sub> (<b>4a</b>), RhCl­(<b>2b</b>)­(CO)<sub>2</sub> (<b>4b</b>), and AuCl­(<b>2a</b>) (<b>5a</b>)were synthesized using <b>2a</b>·HBr and <b>2b</b>·HOTf. …”
  5. 63925
  6. 63926

    DataSheet_1_Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.pdf by Tao Ouyang (735563)

    Published 2021
    “…Hyperthyroidism (OR 3.8, 95%CI 1.7–8.6), nausea (OR 3.7, 95%CI 2.55.3), diarrhea (OR 2.7, 95%CI 2.2–3.2), colitis (OR 3.4, 95%CI 2.7–4.3), ALT increase (OR 4.9, 95%CI 3.9–6.1), AST increase (OR 3.8, 95%CI 3.0–4.9), pruritus (OR 2.4, 95%CI 1.5–3.9), rash (OR 2.8, 95%CI 2.1–3.8), fatigue (OR 2.8, 95%CI 2.2–3.7), decreased appetite (OR 2.4, 95%CI 1.5–3.8), and hypophysitis (OR 2.0, 95%CI 1.2–3.3) were more frequent with combined ICIs. …”
  7. 63927

    New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controll... by Caixia Wang (394572)

    Published 2015
    “…An analysis pooling showed a significant decrease in serum levels of phosphate with calcium-based phosphate binders (CBPBs) by 0.17 mg/dL [mean difference (MD), 95% CI, 0.03, 0.31] than sevelamer. …”
  8. 63928
  9. 63929
  10. 63930
  11. 63931
  12. 63932
  13. 63933
  14. 63934
  15. 63935
  16. 63936
  17. 63937
  18. 63938
  19. 63939
  20. 63940